the aid library

LIST OPTIONS

Filter

10778

Assist - The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)

R. Humeniuk, S. Henry-Edwards, R. Ali; et al. World Health Organization WHO (2010) C_WHO

Manual for use in primary care. There is substantial evidence for the benefits of screening and brief intervention in primary health care for alcohol problems. However, there is a need for screening and brief interventions with cross-cultural relevance for substances other than alcohol or tobacco,... more

Download (349)

View PDF (543)

World Report on Vision

World Health Organization WHO (2019) C_WHO

At present at least 2.2 billion people around the world have a vision impairment, of whom at least 1 billion have a vision impairment that could have been prevented or is yet to be addressed. The world faces considerable challenges in terms of eye care, including inequalities in the coverage and qua... more

Download (247)

View PDF (394)

HIV/AIDS surveillance in Europe 2017

A. Pharris; A. Stengaard World Health Organization (Europe); European Centre for Disease Prevention and Control (2017) C_WHO

2016 data The report was coordinated by Anastasia Pharris and Annemarie Stengaard. Report review and production support were provided by Andrew J. Amato-Gauci, Mike Catchpole, Denis Coulombier, Masoud Dara, Nedret Emiroglu, Rachel Katterl, Shahin Khasiyev, Valentina Lazdina, Teymur Noori, Marc... more

Download (346)

View PDF (348)

Transgender people and HIV

D. Adams; J. Byrne; M. Cabra; et al. World Health Organization (2015) C_WHO

Policy Brief

External Link

Hospital safety Index Guide for Evaluators. Forms

World Health Organization World Health Organization and Pan American Health Organization (2015)

External Link

Buruli Ulcer Prevention of Disability (POD)
recommended

Linda Lehman, Valérie Simonet, Paul Saunderson, and Pius Agbenorku World Health Organization WHO (2006) C_WHO

This manual is for use by doctors, nurses, rehabilitation specialists, National Buruli ulcer Control Programme managers and other health workers involved in the prevention of disability activities in Buruli ulcer. You can download chapters and presentations

Download (530)

View PDF (691)

Progress on drinking water, sanitation and hygiene in schools: 2000-2021 data update

World Health Organization WHO; UNICEF; et al. (2022) C_WHO

Special Focus on COVID-19 The report provides updated estimates for drinking water, sanitation and hygiene in schools including progress from 2015 to 2019. It highlights the rapid improvement needed to ensure students have access to handwashing facilities with soap and water during the COVID-19 pan... more

Download (256)

View PDF (239)

Global Epidemiological Surveillance Standards for Influenza

World Health Organization WHO (2013) C_WHO

Download (371)

View PDF (369)

Multi-Professional Patient Safety Curriculum Guide

World Health Organization WHO (2011) C_WHO

The Multi-professional Patient Safety Curriculum Guide (2011) was developed to assist in the teaching of patient safety in universities and schools in the fields of dentistry, medicine, midwifery, nursing and pharmacy. It also supports the on-going training of all health care professionals. The C... more

Download (855)

View PDF (1874)

Guidance on oral pre-exposure prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstratio

World Health Organization (2012)

Download (307)

View PDF (428)

Innovation in deinstitutionalization: a WHO expert survey

World Health Organization WHO (2014) C_WHO

Based on the survey, five principles for deinstitutionalization were identified: community-based services must be in place; the health workforce must be committed to change; political support at the highest and broadest levels is crucial; timing is key; and additional financial resources are needed.

Download (473)

View PDF (698)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (2548)

View PDF (2781)

WHO-WPR Emergency Response Manual

World Health Organization, Western Pacific Office (2003)

Guidelines for WHO Representatives and Country Offices in the Western Pacific Region

Download (1932)

View PDF (6344)

Hand Hygiene Technical Reference Manual

World Health Organization WHO (2009) C_WHO

A manual to train health-care workers on practising, teaching and observing hand hygiene.

Download (1481)

View PDF (3858)

Birth defects surveillance: Atlas of selected congenital anomalies

World Health Organization (WHO), National Center on Birth Defects and Developmental Disabilities from the United States Centers for Disease Control and Prevention (CDC), International Clearinghouse for Birth Defects Surveillance and Research (ICBDSR) (2014) C_WHO

It provides selected illustrations and photographs of congenital anomalies that are severe enough to have a high probability of being captured during the first few days following birth

Download (603)

View PDF (775)

Epidemic meningitis surveillance in the African meningitis belt

World Health Organization WHO (2014) C_WHO

Download (618)

View PDF (884)

Knowledge, Attitudes and Practice surveys Zika virus disease and potential complications. Resource pack

World Health Organization (2016) C_WHO

This is a resource pack for a Knowledge, Attitudes and Practices (KAP) surveys about Zika virus and its suspected complications such as microcephaly and Guillain-Barré syndrome. This resource and associated advice was requested by governments and response partners as a way to rapidly obtain valuab... more

Download (457)

View PDF (681)

Model disability survey (MDS): survey manual

World Health Organization (WHO) & The World Bank (WB) WHO (2017) CC

The World Health Organization's Model Disability Survey (MDS) Manual is a tool to help implement the MDS in countries and to improve the quality of the interview process. This manual is intended to provide practical information about the survey instruments and their use during interviews. This manua... more

Download (703)

View PDF (637)

Global Tuberculosis Report 2021
recommended

World Health Organization WHO (2021) C_WHO

Each year, the WHO Global TB Report provides a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease, at global, regional and country levels. This is done in the context of global TB commitments, strategies and targets. The... more

Download (259)

View PDF (428)

Monkeypox: Current status in West and Central Africa

World Health Organization (WHO) (2018) C_WHO

Monkeypox is an emerging viral zoonosis with symptoms similar to those observed in smallpox patients, although less severe. Since the global eradication of smallpox in 1980, monkeypox has emerged as the most important orthopoxvirus in humans. The Advisory Committee on Variola Virus Research (ACVVR) ... more

Buruli Ulcer Prevention of Disability (POD) recommended

Global Tuberculosis Report 2021 recommended

Buruli Ulcer Prevention of Disability (POD)
recommended

Global Tuberculosis Report 2021
recommended